At DM2, we recognize the vital role of public trust in the integration of digital technologies in medicine manufacturing. Through our outreach efforts we engaged a local community, gathering insights and addressing concerns about AI and robotics in healthcare. By fostering open dialogue, we aim to shift perceptions, paving the way for a brighter future in medicine.
Read MoreGlobal CDMO Ajinomoto Bio-Pharma Services has become the first organisation to position itself as a Translation to Industry Collaborator within CMAC, a world-leading centre for medicines manufacturing at the University of Strathclyde.
Read MoreCMAC launches campaign encouraging postdoctoral researchers from around the globe, to apply for a prestigious Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.
Read MoreThe EPSRC MediForge Hub will transform the development and manufacturing of medicines by pioneering an Industry 5.0 manufacturing system for sustainable, resilient, and human-centric medicine production.
Read MoreIn a significant stride towards advancing nanoparticle drug delivery manufacturing technology, leon-nanodrugs GmbH (LEON), has proudly announced a pioneering technical evaluation by CMAC, University of Strathclyde.
Read MoreThis ground-breaking CDT is set to revolutionise the pharmaceutical and technology sectors by addressing critical skills needs within the industry.
Read MoreThe University of Strathclyde’s Continuous Manufacturing and Advanced Crystallisation (CMAC) are delighted to announce a new £11 million award from UK Research Partnership Investment Fund (UKRPIF) to deliver the CMAC Data Lab: A Digital Medicine Manufacturing Research Accelerator.
Read MoreIn continuation of our monthly “Meet our Team” post, we are celebrating CMAC’s Operational Coordinator and PA To the Directors, Morell Kerr.
Read More
